Business Club January 24th, the beginning of the new year, the federal pharmaceutical announcement announced: The company received three production approvals for insulin preparations, together with the products that have been approved before, the federal Ulead series currently has four insulin products, and is expected to immediately Mass production and marketing. Coincidentally, the two foreign companies AstraZeneca and Boehringer Ingelheim have just announced their formal entry into the Chinese insulin market. With the appearance of a series of new products and new technologies, the domestic market for hypoglycemic agents, which has been relatively calm, began to flow downward.
New army joins in breaking market calm
The participation of many domestic and foreign companies is precisely the market with great potential. In China, the number of diabetic patients is nearly 100 million, and the incidence rate is more than 10%. The diabetes drug market has passed 10 billion yuan. According to incomplete statistics, the insulin market capacity is also close to 6 billion yuan, while the annual growth rate exceeds 20%. In 2010, China has become one of the fastest growing countries in the world with the highest prevalence of diabetes, and the growth rate is alarming. "Only the Novo Nordisk family has had insulin sales in the Chinese market that exceeded 4 billion yuan in 2009. This market is extremely limited," said one foreign insulin agent.
However, domestic companies only eat up to 5% of this big cake. According to statistics, foreign-funded enterprises accounted for 95% of China's insulin market, and in terms of recombinant human insulin, only Tonghua Dongbao and Ganli Pharmaceutical have entered the market.
Now, domestic companies have already started the counterattack of the insulin market. Cai Jinle, chairman of the federal pharmaceutical company, said: "In the insulin market, domestic companies started relatively late and the overall scale does not have the strength to compete with foreign companies. The federal insulin market will be a new starting point. We are willing to work together with domestic companies to break the Existing pattern."
It is understood that in the current global market of hypoglycemic drugs, the insulin market is basically monopolized by Novo Nordisk, Eli Lilly and Sanofi-Aventis, and the Big Three’s total sales of insulin products are as high as US$8.9 billion, accounting for global insulin 90 % or more of market share. The pattern of China's insulin market is also roughly the same. At the same time, the big three foreign capitals are constantly making efforts in the Chinese market. Novo Nordisk invested 381 million U.S. dollars at the end of 2008 and built the world's largest insulin preparation and filling plant based on the Tianjin plant. Shortly thereafter, in March 2009, Lilly announced that it had invested US$40 million to expand the new plant in Suzhou for the assembly and storage of insulin products. At the same time, Sanofi-Aventis also announced that it will increase its capital by 90 million U.S. dollars, expand the insulin filling production line in Beijing, and increase production capacity to 50 million packaging units. Production is expected to start in 2012.
IMS statistics show that in the field of diabetes medicine in China, Novo Nordisk topped the list with a market share of 35.44%, Sanofi-Aventis and Eli Lilly accounted for 7.91% and 6.28% respectively, while Bayer Thanks to its old product, Sugar Sugar, it also gained 14.85% of the market. At the same time, foreign capital also shows the momentum of accelerating the penetration of China's grass-roots pharmaceutical market.
Antibiotic production giant US Federal Drugs Corp. has made an all-out effort to break into the insulin market and turned it into a calm market. Cai Jinle said that as early as 8 years ago, the company decided to enter the field of bio-pharmaceuticals, and gradually built a research and development team of more than 200 people. “At present, the UWS production lines are all independently designed and developed by us and fully consider the characteristics of the process and energy conservation and environmental protection.†It is understood that U.S. Pharmaceutical has invested heavily in the realization of integrated production from raw materials to formulations to ensure products quality.
In fact, the monopoly structure of the foreign giants in the insulin market in China is not only affected by the rising stars in the country, but also caused some other foreign-funded enterprises to plan to form a “consortium†to open up the Chinese diabetes drug market. Recently, Lilly and Boehringer Ingelheim announced an alliance to jointly promote the sales of new products of the two companies in the Chinese market. AstraZeneca, which does not have hypoglycemic agents, plans to cooperate with Shi Guibao in 2011 to use its marketing advantages to advance the share of Shi Guibao’s diabetes drug market in China.
How local companies compete with foreign companies
Although the size of the Chinese insulin market is rapidly expanding, the market space for domestic companies has been limited, and 95% of the high-end insulin market has been firmly controlled by foreign companies. Although Tonghua Dongbao had announced that it would compete for nearly 50% of China's market when it put into production at the production line with an annual output of 3 tons, its market share did not increase significantly in the past two years, and in the recent procurement of basic drug bidding in Anhui Province, Although 7 kinds of specifications of products have all put down the lowest price, they still have a disappointing result. Foreign drugs are almost completely won. In spite of many achievements in research and development, Ganli Pharmaceutical has focused on the high-end market for insulin analogues, and marketing promotion has not been ideal. Guo Fanli, a research fellow of China Investment Advisor Pharmaceutical Industry, commented on this.
According to industry experts, there are currently more than 100 small and medium-sized insulin manufacturers in the country producing animal insulin with relatively large side effects. "The backwardness of technology makes it difficult for domestic companies to compete with foreign companies." Yu Mingde, president of the China Association of Pharmaceutical Enterprise Management, pointed out that "domestic companies are in the field of insulin, and they need to be technologically superior. At the same time, they are technically stable. Sex must also be increased in order to achieve mass production.†An insulin agency in Henan believes that domestically produced insulin is often over-produced and lacks market competitiveness.
In this regard, Cai Jinle also believes that only enterprises have an advantage in technology and companies have a foothold in the market. "U.S. Pharmaceuticals aimed at the high-end market at the beginning of R&D of recombinant human insulin. The Ulead series products use the most advanced Pichia pastoris expression system." It is reported that the Federation is currently the only company with related technologies in the country and has obtained Four years of technology and product protection.
Guo Fanli believes that if domestic companies want to compete with foreign companies, they not only need to work hard on production technology, but also need to make efforts in R&D and sales channels. On the other hand, diversification, expansion of production capacity, further expansion of overseas markets, and overseas certification are also indispensable. At the same time, we must make full use of the opportunity of the new medical reform to seize the low-end market.
Quality and low price can become winners
In trying to break through the monopoly of foreign capital, the most obvious advantage of domestic companies is the low price. Peng Yu, general manager of the federal pharmaceutical company, said: "Under the guarantee of equivalent efficacy with imported products, the UBS has a greater price advantage." The reporter also seen from the public tender offer in Anhui Province, specifications for 3ml: 300IU , the generic name of "protamine recombinant human insulin injection" products, federal drugs quoted at 49.1 yuan, Lilly offer was 55.8 yuan. The specification is 3 ml: 300 IU (refill) and the generic name is “50/50 mixed recombinant human insulin injectionâ€. Tonghua Dongbao’s offer is 51.50 yuan, and the company’s other 6 insulin products are all quoted at 45.20 yuan. The quotation of several foreign-funded enterprises is more than 53 yuan.
Guo Fanli believes that the distance between foreign companies and prices has always been a competitive advantage for China's insulin companies. Taking UWS as an example, with low cost advantages, product pricing will be about 15% lower than similar products in the market.
However, Tonghua Dongbao, which has a price advantage, encountered a “red light†in the procurement of basic medicines in Anhui Province. Although the lowest price was cast in all 7 formulations, six of them failed to pass. Technical standard review, and lost the opportunity to win the final bid. At the same time, foreign pharmaceutical companies Eli Lilly, Novo Nordisk, and Bayer have become big winners. Of course, the reasons for the failure of cost advantages are complex, but domestic companies should realize that only cost advantages are not feasible, and technologies, brands, and channels are indispensable. Yu Mingde pointed out that although domestic enterprises are in an advantageous position in terms of product prices, there is still room for improvement in sales and services. He said: "Many domestic insulin manufacturers lack a perfect sales network and products cannot cover the market widely. There have been cases where patients want to buy domestic insulin but they have no place to buy."
Professor Tian Haoming of West China Hospital of Sichuan University stated: “Reactive human insulin is used in patients with type 2 diabetes, and short-acting and long-acting recombinant human insulin, mixed recombinant human insulin injection and its analogues are generally used, and patients generally use the same brand. Several products, if the company does not have a full range of products, patients are inconvenient to use.†It is understood that in this regard, although the current domestic companies in the product portfolio can not par with foreign-funded enterprises, but Tonghua Dongbao, Gan Li Pharmaceutical We are constantly enriching our product lines. We have received approval for 3 products from Federal Pharmaceuticals, and we have also formed a full range of recombinant human insulin products.
Huachuang Yang Xiaoxuan said that the insulin market in Europe and the United States is almost saturated, and China has become one of the key markets in the world. Lilly and Novo Nordisk and other giants have been overweight in China. At the same time there are many local newcomers to join, such as Jiangsu Wanbang, a subsidiary of Fosun Pharma. "The future market competition has reached the level of township hospitals." It is reported that Gan Li Pharmaceutical has been Qiming Venture Capital investment over 100 million equity investment, and release the news is expected to be listed within 3 years. Like Fosun Pharma, Tai Chi Group, Hengrui Pharmaceutical, Tasly, Guangpeng, etc., they have made efforts in the field of oral hypoglycemic agents, and the possibility of developing insulin in the future is not ruled out. It can be predicted that the competition in the future insulin market will be very intense.
Regarding the insulin market for local companies, the foreign-invested enterprises surveyed are cautious in their evaluation. However, an industry source stated that people with diabetes often need medication for life. Therefore, high quality and inexpensive insulin products are very important. Only high quality and low price brands can come to the end. Domestic enterprises should strengthen quality improvement on the basis of existing price advantages. "We hope this area can break the monopoly and bring more choices to patients."
New army joins in breaking market calm
The participation of many domestic and foreign companies is precisely the market with great potential. In China, the number of diabetic patients is nearly 100 million, and the incidence rate is more than 10%. The diabetes drug market has passed 10 billion yuan. According to incomplete statistics, the insulin market capacity is also close to 6 billion yuan, while the annual growth rate exceeds 20%. In 2010, China has become one of the fastest growing countries in the world with the highest prevalence of diabetes, and the growth rate is alarming. "Only the Novo Nordisk family has had insulin sales in the Chinese market that exceeded 4 billion yuan in 2009. This market is extremely limited," said one foreign insulin agent.
However, domestic companies only eat up to 5% of this big cake. According to statistics, foreign-funded enterprises accounted for 95% of China's insulin market, and in terms of recombinant human insulin, only Tonghua Dongbao and Ganli Pharmaceutical have entered the market.
Now, domestic companies have already started the counterattack of the insulin market. Cai Jinle, chairman of the federal pharmaceutical company, said: "In the insulin market, domestic companies started relatively late and the overall scale does not have the strength to compete with foreign companies. The federal insulin market will be a new starting point. We are willing to work together with domestic companies to break the Existing pattern."
It is understood that in the current global market of hypoglycemic drugs, the insulin market is basically monopolized by Novo Nordisk, Eli Lilly and Sanofi-Aventis, and the Big Three’s total sales of insulin products are as high as US$8.9 billion, accounting for global insulin 90 % or more of market share. The pattern of China's insulin market is also roughly the same. At the same time, the big three foreign capitals are constantly making efforts in the Chinese market. Novo Nordisk invested 381 million U.S. dollars at the end of 2008 and built the world's largest insulin preparation and filling plant based on the Tianjin plant. Shortly thereafter, in March 2009, Lilly announced that it had invested US$40 million to expand the new plant in Suzhou for the assembly and storage of insulin products. At the same time, Sanofi-Aventis also announced that it will increase its capital by 90 million U.S. dollars, expand the insulin filling production line in Beijing, and increase production capacity to 50 million packaging units. Production is expected to start in 2012.
IMS statistics show that in the field of diabetes medicine in China, Novo Nordisk topped the list with a market share of 35.44%, Sanofi-Aventis and Eli Lilly accounted for 7.91% and 6.28% respectively, while Bayer Thanks to its old product, Sugar Sugar, it also gained 14.85% of the market. At the same time, foreign capital also shows the momentum of accelerating the penetration of China's grass-roots pharmaceutical market.
Antibiotic production giant US Federal Drugs Corp. has made an all-out effort to break into the insulin market and turned it into a calm market. Cai Jinle said that as early as 8 years ago, the company decided to enter the field of bio-pharmaceuticals, and gradually built a research and development team of more than 200 people. “At present, the UWS production lines are all independently designed and developed by us and fully consider the characteristics of the process and energy conservation and environmental protection.†It is understood that U.S. Pharmaceutical has invested heavily in the realization of integrated production from raw materials to formulations to ensure products quality.
In fact, the monopoly structure of the foreign giants in the insulin market in China is not only affected by the rising stars in the country, but also caused some other foreign-funded enterprises to plan to form a “consortium†to open up the Chinese diabetes drug market. Recently, Lilly and Boehringer Ingelheim announced an alliance to jointly promote the sales of new products of the two companies in the Chinese market. AstraZeneca, which does not have hypoglycemic agents, plans to cooperate with Shi Guibao in 2011 to use its marketing advantages to advance the share of Shi Guibao’s diabetes drug market in China.
How local companies compete with foreign companies
Although the size of the Chinese insulin market is rapidly expanding, the market space for domestic companies has been limited, and 95% of the high-end insulin market has been firmly controlled by foreign companies. Although Tonghua Dongbao had announced that it would compete for nearly 50% of China's market when it put into production at the production line with an annual output of 3 tons, its market share did not increase significantly in the past two years, and in the recent procurement of basic drug bidding in Anhui Province, Although 7 kinds of specifications of products have all put down the lowest price, they still have a disappointing result. Foreign drugs are almost completely won. In spite of many achievements in research and development, Ganli Pharmaceutical has focused on the high-end market for insulin analogues, and marketing promotion has not been ideal. Guo Fanli, a research fellow of China Investment Advisor Pharmaceutical Industry, commented on this.
According to industry experts, there are currently more than 100 small and medium-sized insulin manufacturers in the country producing animal insulin with relatively large side effects. "The backwardness of technology makes it difficult for domestic companies to compete with foreign companies." Yu Mingde, president of the China Association of Pharmaceutical Enterprise Management, pointed out that "domestic companies are in the field of insulin, and they need to be technologically superior. At the same time, they are technically stable. Sex must also be increased in order to achieve mass production.†An insulin agency in Henan believes that domestically produced insulin is often over-produced and lacks market competitiveness.
In this regard, Cai Jinle also believes that only enterprises have an advantage in technology and companies have a foothold in the market. "U.S. Pharmaceuticals aimed at the high-end market at the beginning of R&D of recombinant human insulin. The Ulead series products use the most advanced Pichia pastoris expression system." It is reported that the Federation is currently the only company with related technologies in the country and has obtained Four years of technology and product protection.
Guo Fanli believes that if domestic companies want to compete with foreign companies, they not only need to work hard on production technology, but also need to make efforts in R&D and sales channels. On the other hand, diversification, expansion of production capacity, further expansion of overseas markets, and overseas certification are also indispensable. At the same time, we must make full use of the opportunity of the new medical reform to seize the low-end market.
Quality and low price can become winners
In trying to break through the monopoly of foreign capital, the most obvious advantage of domestic companies is the low price. Peng Yu, general manager of the federal pharmaceutical company, said: "Under the guarantee of equivalent efficacy with imported products, the UBS has a greater price advantage." The reporter also seen from the public tender offer in Anhui Province, specifications for 3ml: 300IU , the generic name of "protamine recombinant human insulin injection" products, federal drugs quoted at 49.1 yuan, Lilly offer was 55.8 yuan. The specification is 3 ml: 300 IU (refill) and the generic name is “50/50 mixed recombinant human insulin injectionâ€. Tonghua Dongbao’s offer is 51.50 yuan, and the company’s other 6 insulin products are all quoted at 45.20 yuan. The quotation of several foreign-funded enterprises is more than 53 yuan.
Guo Fanli believes that the distance between foreign companies and prices has always been a competitive advantage for China's insulin companies. Taking UWS as an example, with low cost advantages, product pricing will be about 15% lower than similar products in the market.
However, Tonghua Dongbao, which has a price advantage, encountered a “red light†in the procurement of basic medicines in Anhui Province. Although the lowest price was cast in all 7 formulations, six of them failed to pass. Technical standard review, and lost the opportunity to win the final bid. At the same time, foreign pharmaceutical companies Eli Lilly, Novo Nordisk, and Bayer have become big winners. Of course, the reasons for the failure of cost advantages are complex, but domestic companies should realize that only cost advantages are not feasible, and technologies, brands, and channels are indispensable. Yu Mingde pointed out that although domestic enterprises are in an advantageous position in terms of product prices, there is still room for improvement in sales and services. He said: "Many domestic insulin manufacturers lack a perfect sales network and products cannot cover the market widely. There have been cases where patients want to buy domestic insulin but they have no place to buy."
Professor Tian Haoming of West China Hospital of Sichuan University stated: “Reactive human insulin is used in patients with type 2 diabetes, and short-acting and long-acting recombinant human insulin, mixed recombinant human insulin injection and its analogues are generally used, and patients generally use the same brand. Several products, if the company does not have a full range of products, patients are inconvenient to use.†It is understood that in this regard, although the current domestic companies in the product portfolio can not par with foreign-funded enterprises, but Tonghua Dongbao, Gan Li Pharmaceutical We are constantly enriching our product lines. We have received approval for 3 products from Federal Pharmaceuticals, and we have also formed a full range of recombinant human insulin products.
Huachuang Yang Xiaoxuan said that the insulin market in Europe and the United States is almost saturated, and China has become one of the key markets in the world. Lilly and Novo Nordisk and other giants have been overweight in China. At the same time there are many local newcomers to join, such as Jiangsu Wanbang, a subsidiary of Fosun Pharma. "The future market competition has reached the level of township hospitals." It is reported that Gan Li Pharmaceutical has been Qiming Venture Capital investment over 100 million equity investment, and release the news is expected to be listed within 3 years. Like Fosun Pharma, Tai Chi Group, Hengrui Pharmaceutical, Tasly, Guangpeng, etc., they have made efforts in the field of oral hypoglycemic agents, and the possibility of developing insulin in the future is not ruled out. It can be predicted that the competition in the future insulin market will be very intense.
Regarding the insulin market for local companies, the foreign-invested enterprises surveyed are cautious in their evaluation. However, an industry source stated that people with diabetes often need medication for life. Therefore, high quality and inexpensive insulin products are very important. Only high quality and low price brands can come to the end. Domestic enterprises should strengthen quality improvement on the basis of existing price advantages. "We hope this area can break the monopoly and bring more choices to patients."
The groundbreaking four-chambered structure, differing from the conventional three-chambered structure, has more stable and safer design. The integrated panel design, in combination with the smooth and elegant line type, artistic terminal dust cover design and incomparable production process, creates an aesthetic visual experience and embodies a unique fashion.
Bed Head Unit For Icu,Hospital Bed Head Unit For Icu,Bed Head Units Hospital, Bed Head Hospital Equipment Unit
Hunan Eter Medical Co., Ltd. , https://www.eter-tech.com